Aromatherapy Use to Decrease Functional Nausea and Increase Quality of Life in Pediatric Patients Seen in a Quaternary Care Outpatient Disorder of Gut Brain Interaction Clinic
Erik David Andrewski
Primary Investigator
Brief description of study
What is the purpose of this study?
The purpose of this study is to determine if an outpatient population of pediatric patients with nausea related to a disorder of gut-brain interaction (DGBI) have decreased symptoms after use of aromatherapy (QueaseEase) as measured by the Nausea Profile
Detailed description of study
What will happen during the study?
On their first visit to clinic, treatment will be based on shared decision making between investigator, patient, and caregivers. Based on patient preference, they may receive QueaseEase aromatherapy or start on new medications that exert anti-nausea or neuromodulator effects. They may continue currently prescribed medications if they have persistent nausea, and dosing has been stable for the past 30 days. If patients elect to trial aromatherapy, they may call the gastroenterology clinic at any time to alternate therapies if their preference changes. Before enrollment, patients will fill out a modified DQLQ, a 24-question form validated in the adult population. Patients will be provided a copy of the DQLQ and associated nausea rating scale to take home at their first appointment and have available for follow-up reference. It evaluates the impact of GI symptoms on quality of life over the last seven days, including bloating, pain, and nausea. The modified version will evaluate effects of only nausea on daily life.
Patients will be provided with QueaseEase QuickTAB and QuickCLIP System free of charge to be used as needed for nausea over the next two weeks. All patients will be verbally instructed and provided with a handout on how to use QueaseEase. At the end of the two-week period, one of the investigators will contact the patient via phone to obtain results of the modified DQLQ while using aromatherapy and evaluate patient satisfaction and perceived nausea relief from QueaseEase via standardized template.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Functional nausea, Riley
-
Age: 9 years - 18 years
-
Gender: All
Inclusion Criteria
Age 9-18 at time of enrollment
Diagnosis of functional nausea as specified by the Rome IV criteria 11
English speaking
Exclusion Criteria
Allergy to QueaseEase or any of its components
Anosmia (inability to smell)
Pregnancy
Change in anti-nausea medications or dosing over the past 30 days
